Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -4.68% | -3.34% | -6.28% | -11.46% | -11.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.68% | -3.34% | -6.28% | -11.46% | -11.17% |
| Cost of Revenue | -11.25% | -8.94% | -6.90% | -9.74% | -1.54% |
| Gross Profit | 0.49% | 0.84% | -5.83% | -12.75% | -17.52% |
| SG&A Expenses | -1.17% | -21.94% | -16.76% | -20.58% | -14.42% |
| Depreciation & Amortization | -29.31% | -32.38% | -35.91% | -12.70% | -12.98% |
| Other Operating Expenses | -- | -- | -- | -- | -82.30% |
| Total Operating Expenses | -7.28% | -15.30% | -14.02% | -14.94% | -12.66% |
| Operating Income | 42.18% | 624.40% | 114.45% | 63.00% | 28.74% |
| Income Before Tax | 93.49% | -643.05% | 74.75% | 31.28% | -1,032.78% |
| Income Tax Expenses | 125.77% | -162.41% | -68.81% | 107.93% | -316.19% |
| Earnings from Continuing Operations | 93.20% | -15,916.67% | 74.36% | 22.04% | -972.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.20% | -15,916.67% | 74.36% | 22.04% | -972.43% |
| EBIT | 42.18% | 624.40% | 114.45% | 63.00% | 28.74% |
| EBITDA | 1,225.81% | 110.68% | 1,207.50% | 678.91% | 106.22% |
| EPS Basic | 93.29% | -15,668.29% | 74.90% | 23.47% | -955.48% |
| Normalized Basic EPS | -10.14% | -443.96% | 75.35% | 22.53% | 14.69% |
| EPS Diluted | 93.26% | -15,668.29% | 72.75% | 23.47% | -938.18% |
| Normalized Diluted EPS | -10.14% | -450.29% | 75.35% | 22.53% | 14.69% |
| Average Basic Shares Outstanding | 1.43% | 2.16% | 2.16% | 1.88% | 1.61% |
| Average Diluted Shares Outstanding | 1.43% | 0.33% | 2.16% | 1.88% | 1.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |